| Henrik Ehlers Wulff |
Henrik Ehlers Wulff is currently the Chairman at Novo Nordisk Production SAS and Novo Nordisk. Pharmatech A. He is also an Independent Director at Ambu A, a Director at Grundfos Holding A, and a Director at Grundfos Americas Corp. In 2019, he became the Executive VP-Product Supply, Quality & IT at Novo Nordisk A. Previously, he held positions as a Director at NNE A and NNE Pharmaplan A. Mr. Wulff graduated from the Technical University of Denmark in 1995. |
| Karsten Munk Knudsen |
Karsten Munk Knudsen is currently the Chairman at NNE A, Novo Nordisk Region Aameo & Latam A, Novo Nordisk Region Europe A, Novo Nordisk North America Operations A, and Director at Hempel A. He previously worked as the Principal at A.P. Møller-Mærsk A, Financial Analyst at Nykredit Bank A, Member-Supervisory Board at Innate Pharma SA, VP-Finance & Information Technology at Novo Nordisk, Inc. from 2010 to 2014, and Head-Finance at NNIT A. Mr. Knudsen obtained a graduate degree from the University of Aarhus in 1998. |
| Maziar Mike Doustdar |
Maziar Mike Doustdar is currently the Director at Orion Oyj and the Managing Director at Novo Nordisk Health Care AG. He previously worked as the Executive Vice President-International Operations at Novo Nordisk A from 1992 to the present. Before that, he was a Member at the European Federation of Pharmaceutical Industries & Assns from 2016 to 2021. He also held the position of EVP & Head-International Operations at Novo Nordisk Ltd. Mr. Doustdar completed his undergraduate degree at Webster University in 1994. |
| Liselotte Hyveled |
Liselotte Hyveled is currently the Chief Patient Officer & Non-Independent Director at Novo Nordisk A. She is also a Director at RSP Systems A and an Independent Director at TriSalus Life Sciences, Inc. starting in 2024. Previously, she worked as a Director at Novo Nordisk A from 1992 to 2018, with a specific role as Director from 2014 to 2018. She also held a Director position at Novo Nordisk Ltd. Ms. Hyveled completed her graduate degree at Copenhagen Business School in 2011 and another graduate degree at the University of Copenhagen in 1992. |
| Marcus Schindler |
Marcus Schindler's career history includes current and former positions as well as his education history. Currently, he is the Chief Scientific Officer & Executive VP-Research at Novo Nordisk A since 2021. Previously, he worked as the Head-Research at The Oxford. From 2018 to 2021, he was a Member-Supervisory Board at Innate Pharma SA. He also served as the Head-Research at Prosidion Ltd. and as the Vice President & Head-Cardiovascular at AstraZeneca A. In terms of education, Dr. Schindler obtained a doctorate degree from the University of Cambridge in 1997 and a graduate degree from the University of Gottingen in 1994. |
| Stephen Gough |
Stephen Gough has worked as the Global Chief Medical Officer at Novo Nordisk A since 2015. |
| Helge Lund |
Helge Lund is currently the Chairman at BP Plc, BP Canada Energy Group ULC, Novo Nordisk A, BP Oil Australia Pty Ltd., Inkerman Holding AS, Tjaldur P, Belron Group SA, Clayton Dubilier & Rice LLC, International Crisis Group, European Round Table of Industrialists, and BP Technology Ventures Ltd. He is also a Trustee at The International Crisis Group (United States). Previously, Mr. Lund served as the Chief Executive Officer & Executive Director at BG Group Ltd. from 2015 to 2016. He was the President & Chief Executive Officer at Equinor ASA from 2004 to 2014. He also held the position of Chief Executive Officer-Oil Services at Schlumberger GmbH from 2016 to 2018 and President & Chief Executive Officer at Akastor ASA from 2002 to 2004. Additionally, he served as Chairman at BP America, Inc. and Independent Non-Executive Director at Nokia Oyj from 2011 to 2014. He was an Independent Non-Executive Director at Schlumberger NV from 2016 to 2018 and an Independent Director at Novo Nordisk A from 2014 to 2015. He has also held various other directorial positions. Mr. Lund holds an MBA from INSEAD, which he obtained in 1991. He also graduated from the Norwegian School of Economics & Business Administration in 1987. |
| Lars Fruergaard Jørgensen |
Lars Fruergaard Jørgensen currently works at Novo Nordisk A, as President & Chief Executive Officer from 2017, Novo Nordisk Ltd., as President & Chief Executive Officer from 2004, Harno Invest A, as Chairman, European Federation of Pharmaceutical Industries & Assns, as Vice President from 2021, and Federation Européenne D'Associations Et D'Industries Pharma, as President. Mr. Jørgensen also formerly worked at Carlsberg A, as Vice Chairman-Supervisory Board, Carlsberg Breweries A, as Vice Chairman-Supervisory Board, NNE Pharmaplan A, as Vice Chairman, ZymoGenetics, Inc., as Director in 2010, NNIT A, as Director from 2005 to 2015, Innate Pharma SA, as Member-Supervisory Board from 2007 to 2013, and Novo Nordisk SAS, as Vice President-Finance & Information Technology in 2004. Mr. Jørgensen received his graduate degree in 1991 from the University of Aarhus. |
| Andreas Fibig |
Mr. Andreas Fibig is an Independent Director at ExlService Holdings, Inc., an Independent Director at Novo Nordisk A/S, a Chairman at German American Chamber of Commerce, Inc., a Chairman at Max Planck Institute For Infection Biology and a Member at German Academy of New York. He is on the Board of Directors at Montai Health, Inc., ExlService Holdings, Inc., Indigo Ag, Inc., Evodiabio ApS, Novo Nordisk A/S, European Federation of Pharmaceutical Industries & Assns and World Business Council for Sustainable Development. Mr. Fibig was previously employed as an Independent Director by Bunge Ltd., a Chairman & Chief Executive Officer by International Flavors & Fragrances, Inc., a President & Chairman-Management Board by Bayer HealthCare Pharmaceuticals, Inc., a Chairman by Bayer Pharma AG, a Senior VP-US Pharmaceutical Operations Group by Pfizer Inc., a President-Market by Pharmacia GmbH, a Principal by Boehringer Ingelheim GmbH, a Director-Sales & Marketing by Bayer Schering Pharma AG, and a Member-Supervisory Board by Verband Forschender Arzneimittelhersteller eV. He also served on the board at Council of the Americas, Inc. He received his undergraduate degree from Hochschule für Wirtschaft und Recht Berlin. |
| Laurence Debroux |
Laurence Debroux is currently an Independent Director at Novo Nordisk A, a Director at École des Hautes Études Commerciales de Paris, the Chief Financial Officer & Director at Dibevit Import Srl, a Director at JCDecaux Bollore Holding SAS, a Director at Bpifrance Participations SA, an Independent Non-Executive Director at EXOR NV, and a Member-Supervisory Board at Randstad NV. Ms. Debroux previously served as an Independent Director at Solvay SA, the Chief Financial Officer & Director at Heineken NV, a Director at APG SGA SA, a Director at Juventus Football Club SpA, an Independent Director at Natixis SA, a Director at Média Aéroports de Paris SAS, the Chief Financial & Administrative Officer at JCDecaux SE, the Chief Financial Officer at Heineken Holding NV, and the Chief Financial & Strategic Officer at Sanofi SA. Ms. Debroux also served as a Member-Supervisory Board at MediaKiosk SAS. Ms. Debroux graduated from École des Hautes Études Commerciales de Paris in 1992. |
| Christina Law |
Christina Law is currently an Independent Director at Novo Nordisk A, Air Liquide SA, Raintree Group Ltd., Insead Business School, Raintree Investment Pte Ltd., and La Fondation Des Champions. She previously served as an Independent Director at Air Liquide Tunisie SA, Group President-Asia at General Mills, Inc., and Vice President at Johnson & Johnson. She also held the position of Head-Marketing at Proctor & Gamble from 1992 to 2003. Ms. Law obtained her undergraduate degree from the University of Hong Kong in 1988 and an MBA from INSEAD in 1991. |
| Martin W. MacKay |
Dr. Martin W. MacKay is an Independent Director at Springworks Therapeutics, Inc., an Independent Director at Novo Nordisk A/S, a Chairman & Chief Executive Officer at Rallybio LLC, an Executive Chairman at Rallybio Corp., a Chief Executive Officer at Calyx Group Ltd. (Ireland), a Chief Executive Officer & Director at Rallybio Holdings LLC and an Independent Director at Charles River Laboratories, Inc. He is on the Board of Directors at Springworks Therapeutics, Inc., Novo Nordisk A/S, Charles River Laboratories International, Inc., Rallybio Holdings LLC and Charles River Laboratories, Inc. Dr. MacKay was previously employed as an Independent Director by 5:01 Acquisition Corp., a Senior Advisor by New Leaf Venture Partners LLC, a Global Head-Research & Development by Alexion Pharmaceuticals, Inc., a Chief Executive Officer & Director by Neverfail, Inc., a President-Research & Development by AstraZeneca PLC, a President by Pfizer (St. Louis), a Senior Vice President-Worldwide Development by Pfizer Inc., a Head-Molecular & Cell Biology by CNS Research Institute P.C., a Head-Drug Preformulation & Delivery by Ciba-Geigy Pharmaceuticals, a Principal by Accenture LLC, a Head-Drug Preformulation & Delivery by BASF Performance Products Ltd. (United Kingdom), a Principal by Beecham Pharmaceuticals (UK), a Chief Executive Officer & Director by Neverfail Ltd., a Director-Business Development by NorthgateArinso, Inc., a Principal by PeopleSoft USA, Inc., an Operations Director by The Dun & Bradstreet Corp., a Chief Executive Officer by Vecta Software Corp. Ltd., and a Vice President-International by VeriSign, Inc. He also served on the board at Encysive Pharmaceuticals, Inc. He received his undergraduate degree from Heriot-Watt University and a doctorate degree from The University of Edinburgh. |
| Sylvie Louise Grégoire |
Sylvie Louise Grégoire is the founder and currently holds multiple positions. She is the Executive Chairman of EIP Pharma, Inc., which she founded in 2010. She is also the Chairman of Corvidia Therapeutics, Inc., Abivax SA, and Novo Nordisk A. In addition, she serves as a Director at F2G Ltd., CervoMed, Inc., and Shire Orphan Therapies GmbH. Dr. Grégoire has held several former positions, including President, CEO & Executive Director at GlycoFi, Inc. from 2004 to 2005, Executive Chairman at IDM Pharma, Inc. from 2006 to 2007, and Independent Director at Cubist Pharmaceuticals LLC from 2006 to 2011. She has also served as a Non-Executive Director at Vifor Pharma AG and held director positions at Thallion Pharmaceuticals, Inc., CellCarta Biosciences, Inc., Vifor Pharma Management AG, and Novo Nordisk Ltd. Dr. Grégoire's education includes a doctorate from the State University of New York at Buffalo in 1986, an undergraduate degree from Université Laval in 1984, and an undergraduate degree from Séminaire de Sherbrooke in 1980. |
